RapidPulse closes $48m Series B to advance TURBO stroke trial

The Miami medtech secured an oversubscribed round co-led by Medtronic to fund its IDE study of pulsed aspiration thrombectomy and pursue FDA clearance.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
Medical vials, a clear tube, and a syringe rest on a light blue surgical drape in a brightly lit clinical setting, with a large monitor displaying a blue-toned brain scan in the background.

RapidPulse, Inc. has closed a $48 million Series B financing to accelerate clinical development of its pulsed aspiration thrombectomy system for acute ischaemic stroke. The round was oversubscribed and co-led by Medtronic, Italian operational holding company TechWald Next S.p.A., and Austin-based S3 Ventures. Returning backers Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital participated alongside new entrants SBI Investment Company and the Florida Opportunity Fund.

The proceeds will fund completion of the company's ongoing Investigational Device Exemption study, formally titled the Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions (TURBO) trial, which is running at stroke centres in both the United States and Europe. RapidPulse said the capital will also support expansion of its catheter platform across a full range of sizes. Data from the TURBO study are intended to underpin a US regulatory submission.

The technology and its rationale

RapidPulse's system applies a controlled cyclic, or pulsed, aspiration approach to clot engagement and removal during mechanical thrombectomy, rather than the continuous suction used by conventional aspiration catheters. The company says the technique is designed to improve clot capture and procedural consistency, though no peer-reviewed efficacy data have been published; all claims at this stage are based on preclinical work and early clinical experience. The TURBO study represents the pivotal data-generating event for the programme.

Chief executive Sean McBrayer said the round gives the company what it needs to complete the TURBO study, broaden its footprint at leading stroke centres, and, subject to data, seek FDA approval. He pointed to Medtronic's co-lead position as evidence of growing strategic interest in the pulsed aspiration approach. RapidPulse was spun out of Syntheon, a Miami-based medical device incubator.

Market context and competitive landscape

Mechanical thrombectomy for large vessel occlusion stroke is a well-established and growing market, with leading positions held by Medtronic itself (through its Solitaire and React platforms), Stryker (Trevo and Catalyst), and Penumbra (the dominant aspiration-first player with its ACE and Lightning systems). The segment has attracted sustained venture and strategic investment over the past decade as interventional volumes grow alongside rising awareness and expanding thrombectomy-capable hospital networks.

Medtronic's decision to co-lead this round rather than simply observe is notable. Large-cap medtech companies increasingly use Series B co-investments as a structured option on emerging technology, particularly in neurovascular, where stent retriever and aspiration technologies continue to evolve. For RapidPulse, that backing provides not just capital but a potential commercialisation pathway; for Medtronic, it positions the company to acquire or licence the technology if TURBO data are positive.

The IDE study pathway for stroke devices has become more clearly defined following recent FDA guidance on stroke thrombectomy trial design, and the agency has approved several next-generation devices in the category over the past three years. Investors will be watching for TURBO enrolment pace, first-pass reperfusion rates, and any safety signals as near-term indicators of the programme's trajectory ahead of a regulatory filing.

Topic

Geography